Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension

Suzuki, Katsuyoshi; Otsuka, Naruhito; Hizaki, Hiroko; Hashimoto, Michie; Kuwayama, Yasuaki; Latanoprost, Timolol Versus

doi:10.1007/s12325-018-0718-9

Cited by 11 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A further study in which patients were switched from LTFC to a fixed combination of tafluprost/timolol (TTFC) found no significant difference in IOP after the switch. 7 This result was similar to that of the meta-analysis, which found no difference in IOP-lowering efficacy between latanoprost and tafluprost and a significant decrease in reports of eye irritation and eye pain after switching to TTFC. 6 Another meta-analysis reported that the IOPlowering efficacy of a fixed combination of bimatoprost/timolol was better than that of LTFC and TTFC and that conjunctival hyperemia was less common with LTFC than with the fixed combination of bimatoprost/timolol.…”

Section: Discussionsupporting

confidence: 87%

<p>Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination</p>

Inoue

Piao

Iwasa

et al. 2020

OPTH

View full text Add to dashboard Cite

To investigate the short-term intraocular pressure-lowering efficacy and safety of switching from a fixed combination of latanoprost/timolol to a fixed combination of latanoprost/carteolol. Patients and Methods: The subjects were 30 eyes of 30 adult patients with primary openangle glaucoma, normal-tension glaucoma, or ocular hypertension who were using a latanoprost-/timolol-fixed combination with insufficient intraocular pressure-lowering efficacy or adverse reactions. The subjects were switched from once-daily latanoprost/timolol to once-daily latanoprost/carteolol with no washout interval. Intraocular pressure, tear film break-up time, corneal epithelial defects, conjunctival hyperemia, blood pressure, and pulse rate were measured and compared before and 1 and 3 months after switching. Patients were monitored for adverse reactions at each visit, and dropouts were recorded. Results: The mean intraocular pressure at 1 month (15.9±3.1 mmHg) and 3 months (16.3 ±3.8 mmHg) was not significantly different from that at baseline (16.1±3.1 mmHg). The tear film break-up time and corneal epithelial defects were significantly improved after switching (p<0.01 and p<0.0001, respectively). There was a significant decrease in systolic blood pressure after 1 month and diastolic pressure after 3 months (p<0.05). There was no significant change in pulse rate during the study. Adverse reactions (blurred vision, blepharitis, and conjunctival hyperemia) occurred in 3 patients (10.0%). Four patients (13.3%) discontinued treatment during the 3-month study period. Conclusion: A switch from a fixed combination of latanoprost/timolol to that of latanoprost/ carteolol can maintain intraocular pressure and adherence with once-daily administration while improving tear film break-up time and corneal epithelial defects.

show abstract

Section: Discussionsupporting

confidence: 87%

<p>Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination</p>

Inoue

Piao

Iwasa

et al. 2020

OPTH

View full text Add to dashboard Cite

show abstract

“…However, according to previous reports, 2% dorzolamide and 1% brinzolamide share similar IOP-lowering efficacies [11], and those of 0.005% latanoprost and 0.0015% tafluprost are comparable as well [12][13][14]. Suzuki et al [15] reported randomized controlled study results comparing the efficacy and safety of a tafluprost/timolol fixed combination and a latanoprost/timolol fixed combination. In their study, there were no significant differences observed between the two groups in terms of IOP, superficial punctate keratopathy score, tear breakup time, or hyperemia score after 12 weeks.…”

Section: Discussionmentioning

confidence: 98%

Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma

Kim

Jeoung

et al. 2020

Korean J Ophthalmol

View full text Add to dashboard Cite

We sought to compare the efficacy as well as the safety of two maximum medical therapy combinations applied to lower the intraocular pressure (IOP) in different primary open-angle glaucoma (POAG) age groups. Methods: This was a retrospective, consecutive case series study that included 60 eyes of 60 subjects with POAG, specifically 20 subjects aged 40 to 54 years, 21 aged 55 to 69 years, and 19 aged 70 years or older. All had been treated for at least 12 months with triple maximum medical therapy (TMT; dorzolamide/timolol, brimonidine, and latanoprost) to lower their IOP, which subsequently was changed to double maximum medical therapy (DMT, fixed drug combinations of tafluprost/timolol and brinzolamide/brimonidine). The rate of IOP change and adverse drug reactions were compared amongst the three age groups. Results: The mean IOP change at three months after converting from TMT to DMT was-0.65 ± 1.42 mmHg (-3.84% ± 9.31%) among the overall study group, but this finding was not statistically significant (p = 0.108). In the 40 to 54 years and 55 to 69 years groups, the mean IOP change rates were +0.29 ± 0.96 mmHg (+2.40% ± 6.85%, p = 0.087) and-0.50 ± 0.99 mmHg (-3.05% ± 6.40%, p = 0.084) respectively. In the 70 years or older group, the mean IOP change, interestingly, was-1.80 ± 1.46 mmHg (-11.29% ± 9.31%, p < 0.001) and nine (47.4%) of the 19 subjects showed additional IOP reductions of 10% or more after converting from TMT to DMT. In all three age groups, the incidence rate of dry eye was significantly lower for DMT than for TMT (p = 0.031). Conclusions: In POAG patients, DMT was proven to be both effective and safe for lowering the IOP, especially in those 70 years or older group, when compared with the TMT protocol.

show abstract

“…Second, our meta-analysis did not include all the different fixed combinations. An open-label study reported the difference between a tafluprost/timolol fixed combination and LTFC, with 131 patients who were followed up for three months [12]. This study found that the IOP before and 4-6 hours after administration were not significantly different.…”

Section: Discussionmentioning

confidence: 86%

“…We then screened each of these 19 articles for their content and methodological qualities. Based on our thorough screening, we excluded one article because LTFC was used only as a run-in treatment before the randomization [11] and another article because it is an open-label study [12]. As a result, a total of 17 articles describing 17 clinical trials that addressed LTFC versus other anti-glaucoma fixed combinations for POAG and OHT patients were included in the systematic review, and 16 of these articles were included in the meta-analysis.…”

Section: Search For Relevant Studiesmentioning

confidence: 99%

The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background Fixed-combination (FC) therapy is used in primary open-angle glaucoma (POAG) and ocular hypertension (OHT) patients who require more than one medication to reach their target intraocular pressure (IOP). Currently, there are several FC therapies available for the treatment of glaucoma. The FC of latanoprost/timolol (LTFC) is a commonly used FC. Here, we conducted systematic review to compare the IOP-lowering effects of LTFC with other FCs for patients with POAG and OHT. Materials and methods We searched PubMed, EMBASE, the Cochrane Library, and Web of Science for randomized-controlled clinical trials and cross-over studies. The outcomes were mean IOP and IOP fluctuation after one month of treatment. Meta-analysis was carried out using RevMan (version 5.1) software. After conducting meta-analyses, we rated the quality of each meta-analysis as high, moderate, low, or very low using the "GRADE" system. Results We included 16 trials in this meta-analysis. Moderate-quality meta-analysis showed that LTFC had a comparable mean IOP to that of a fixed combination of travoprost and timolol (TTFC) [mean difference (MD): 0.07 mmHg] and a fixed combination of dorzolamide and timolol (DTFC) [MD: −0.31 mmHg], and it also had a comparable IOP-fluctuation effect compared to that of TTFC [MD: 0.13 mm Hg] and DTFC [MD: 0.25 mmHg]. Compared to the fixed combination of bimatoprost and timolol (BiTFC), moderate-quality evidence showed a higher mean IOP in the LTFC group [MD 0.76 mmHg], whereas low-quality meta-analysis showed higher IOP fluctuation [MD 1.09 mmHg] in the LTFC group.

show abstract

Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension

Abstract: Santen Pharmaceutical Co., Ltd., Osaka, Japan.

Cited by 11 publications

References 27 publications

<p>Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination</p>

<p>Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination</p>

Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma

The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis

Contact Info

Product

Resources

About